Cumulative relapse incidence depending on CMV reactivation, in vivo T cell depletion and disease stage. (A) Patient cohort without ATG (n = 420). (B) Patient cohort with ATG (n = 267). (C) Advanced disease stages subgroup without ATG (n = 256). (D) Advanced disease stages subgroup with ATG (n = 138). (E) AML in CR1 subgroup without ATG (n = 164). (F) AML in CR1 subgroup with ATG (n = 129). Cumulative incidence function of relapse (60 months censored) depending on CMV reactivation (blue) and absence of CMV reactivation (red). Median (line) with 95% confidence interval (CI) shaded. All P values refer to comparisons of strata with Gray’s test.